Long noncoding RNAs (lncRNAs) are involved in the pathology of various tumours, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanisms of their specific association with NSCLC have not been fully elucidated.
remains poor. 3 Thus, exploration of the molecular mechanisms and molecules involved in the development and progression of NSCLC may provide valuable therapeutic targets for these diseases.
It has been shown that protein-coding genes occupy only a small proportion (1%-2%) of the human genome. The rest are nonprotein-coding transcripts including small noncoding RNAs and long noncoding RNAs (lncRNAs). 4 LncRNAs have gradually been shown to be pivotal molecules that affect cancer development and progression. 5 The length of lncRNAs is longer than 200 nucleotides (nt), yet this class of RNA has limited coding potential. 6 LncRNAs function in a wide range of biological processes and can regulate gene expression through diverse mechanisms. 7 It has been suggested that cytoplasmic lncRNAs are important molecules in regulating cancer intracellular signaling pathways. 8 For example, the lncRNA MAYA modulates the methylation status of MST1 leading to bone metastasis. 9 The lncRNA lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. 10 Epidermal growth factor receptor (EGFR), a transmembrane glycoprotein with tyrosine kinase activity is often aberrantly activated by mutation or overexpression in many human cancers. 11 Over 60%
of the NSCLC cases show EGFR overexpression, which is associated with poor prognosis of NSCLC. 12, 13 Ligand-activated EGFR leads to stimulation of intracellular cascades, such as the RAS/RAF/ERK and PI3K/AKT signaling pathways. Abnormally activated EGFR drives the malignant phenotype including cell proliferation, survival, invasion and migration. 13 Although several lncRNAs have been reported to modulate tumour proliferation, apoptosis or metastasis, the specific mechanisms of lncRNA involvement in EGFR signaling pathway- Table S1 .
| Tissue specimens

| Plasmids and generation of stable cell lines
Full-length DUXAP9-206 was synthesized by Genewiz (Suzhou, China) and was inserted into the pSin-EF2-puro retroviral vector 293FT cells was performed with a standard calcium phosphate transfection method as previously described. 14 Briefly, the cells were transfected for 24 hours and supernatants were collected and incubated with the indicated cells with polybrene (2.5 μg/mL). Positive cells were selected with puromycin (1.5 μg/mL) for 10 days.
| Small interfering RNAs
All siRNAs were synthesized by RiboBio (Guangzhou, China) and used at a final concentration of 100 nmol/L. The sequences of the siRNAs are summarized in Table S3 .
| 5′ and 3′ rapid amplification of cDNA ends PCR
Total RNA extracted from human A549 and H1703 cells was subjected rapid amplification of cDNA ends polymerase chain reaction (RACE PCR) (Ambion, Austin, TX, USA) according to the manufacturer's specifications. Gene-specific primers used for the PCR of RACE analysis are listed in Table S4 .
| Cell nucleus/cytoplasm fraction isolation
Cell nucleus/cytoplasm fraction isolation was performed using Nuclear and Cytoplasmic Extraction Kit (Ambion). In brief, cells were washed with ice-cold PBS two times and then ice-cold CERI, CERII and NER reagents were added sequentially. After vortex and short centrifugation, the supernatant was collected as cytoplasmic fraction and the remainder with additional washing was considered as nuclear pellets. 
| Co-immunoprecipitation
The indicated cells were collected and lysed with cell lysis buffer 
| Wound healing and transwell assays
For wound healing assays, the indicated cells were plated in 6-well plates and then, streaks were created with a pipette tip. After scratching, wells were gently washed with PBS twice and incubated in DMEM supplemented with 1% FBS. Progression of migration was observed and photographed at 24 hours after wounding.
Cell invasion and migration assays were performed using a 24- 
| Cell proliferation assay
For colony formation assays, the indicated cells were plated in sixwell plates (5 × 10 2 cells) and cultured for 10 days. Then, the cells were fixed with 4% formaldehyde for 15 minutes and stained with 0.1% crystal violet for 10 minutes. 
| Tumour xenografts and metastasis models
All experimental procedures were approved by the Institutional Ani- isoflurane. Sixty days after tumour implantation, the mice were killed and the lungs were collected to count surface metastases. Extracted lungs were fixed in formalin and embedded in paraffin using a conventional method for further histological hematoxylin and eosin (H&E) staining.
| In situ hybridization and immunohistochemistry
Formalin-fixed, paraffin-embedded NSCLC samples were fixed in 4% paraformaldehyde and incubated with proteinase K for 20 minutes at 37°C. After they were dewaxed and rehydrated, the samples were hybridized with 40 nmol/L digoxin-labelled DUXAP9-206 probe (Exiqon, for sequence, see Table S6 ) at 55°C overnight. The slides were then washed with SSC buffer and incubated with anti-digoxin monoclonal antibody (Roche) for 1 hour at room temperature followed by staining with Nuclear Fast Red solution.
Immunohistochemistry assays were performed and quantified as previously described 17 
| Statistical analysis
All statistical analyses were carried out using the SPSS 20.0 statistical software package. Survival curves were analysed by the KaplanMeier method and a log-rank test was used to assess significance.
The correlation between the expression levels of DUXAP9-206 and clinical parameters of patients was assayed by a chi-squared test.
Student's t test was used to compare between groups. In all cases, error bars represent the mean ± SD derived from three independent experiments. P values <0.05 were considered statistically significant.
| RESULTS
| DUXAP9-206 is up-regulated in NSCLC and correlates with patients' survival
To explore the functional and clinical relevance of DUXAP9-206 in NSCLC, we initially analysed the expression levels of DUXAP9-206.
In situ hybridization (ISH) analysis using a specific probe revealed that the expression levels of DUXAP9-206 were significantly elevated in NSCLC tumour tissues compared with paired adjacent nontumour tissues ( Figure 1A) . The level of DUXAP9-206 in NSCLC tissues was further verified by qRT-PCR assays with specific primer ( Figure 1B) . Consistently, DUXAP9-206 was highly expressed in NSCLC cell lines compared with normal lung epithelial cells (BEAS-2B) ( Figure 1C) . Moreover, in a set of 216 NSCLC patients in the Sun Yat-sen University Cancer Center (SYSUCC) cohort (Table S1) for whom overall survival data were available, patients with high Taken together, these data strongly suggest that DUXAP9-206 may act as a driver molecule to promote NSCLC metastasis and proliferation.
| DUXAP9-206 directly interacts with Cbl-b in the cytoplasm
We next sought to explore the possible mechanism underlying the role of DUXAP9-206 in regulating NSCLC progression in cytoplasmic processes. Previous studies have extensively shown that many Majority of the NSCLC patients worldwide are EGFR wild type. 34 However, numerous receptor tyrosine kinase inhibitors target mutation-positive NSCLC 35, 36 and wild type EGFR patients lack effective treatments that significantly improve their survival and prognosis. 13, 34 In this study, DUXAP9-206 was found to inhibit the degradation of EGFR in EGFR wild type NSCLC cells, such as A549 and H1703, indicating that DUXAP9-206 may be a promising therapeutic target for EGFR wild type patients in NSCLC. To further validate this result, we will collect wild type EGFR specimens from patients with NSCLC to compare the expression of DUXAP9-206 with normal patient specimens, verify their relationship with relevant signaling pathways and analyse the correlation with survival and prognosis of patients. Whether this mechanism also plays an important regulatory role in the EGFR mutant patients should be investigated further.
In summary, our study indicates that DUXAP9-206 and its regulated pathway is crucial for NSCLC and targeting DUXAP9-206 may be pivotal in the diagnosis or treatment of NSCLC.
